Poster Abstract Session:
146. HIV: New Antiretrovirals
Friday, October 9, 2015: 12:30 PM-2:00 PM
Room: Poster Hall

Learning Objectives:

-

Tracks: Pediatric ID, HIV-STD-TB, Adult ID

Presentations:
Safety and Efficacy of TAF vs. TDF Single-Tablet Regimen in HIV-1 Treatment-Na´ve Black and non-Black Patients through Week 48
David Alain Wohl, MD ; Joseph Gathe, MD ; Melanie Thompson, MD ; Robert Grossberg, MD ; Sorana Segal-Maurer, MD ; Laurent Cotte, MD ; Indira Brar, MD ; Susan Guo, PhD ; Devi Sengupta, MD ; Marshall Fordyce, MD
Influence of Age on Outcomes in HIV-infected Adults Initiating Tenofovir Alafenamide Fumarate (TAF) versus Tenofovir Disoproxil Fumarate (TDF) with Elvitegravir, Cobicistat, and Emtricitabine (E/C/F/TAF vs. E/C/F/TDF)
Eric S. Daar, MD ; Michael Saag, MD, FIDSA ; Benoit Trottier, M.D. ; Amanda Clarke, M.D. ; Edwin Dejesus, MD, FACP, FIDSA ; David Parks, M.D. ; Eugenio Teofilo, M.D. ; Cynthia Brinson, M.D. ; Hal Martin, M.D., M.P.H. ; Susan Guo, PhD ; Sandra Friborg, B.S. ; Marshall Fordyce, MD
HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 48 Subgroup Analysis
Judith Feinberg, MD ; Jacob Lalezari, MD ; Marcelo Martins, MD ; Martin Casapia, MD, MPH ; David Stock, PhD ; Cyril Llamoso, MD ; Samit Joshi, DO MPH ; George Hanna, MD ; Max Lataillade, DO MPH

CME Credits:

ACPE Credits:

ACPE Number:


Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.